Hecht Anna, Nowak Daniel, Nowak Verena, Hanfstein Benjamin, Büchner Thomas, Spiekermann Karsten, Weiß Christel, Hofmann Wolf-Karsten, Lengfelder Eva, Nolte Florian
Department of Hematology and Oncology, University Hospital Mannheim, University of Heidelberg, Germany.
Department of Hematology and Oncology, University Hospital Mannheim, University of Heidelberg, Germany.
Leuk Res. 2015 Aug 20. doi: 10.1016/j.leukres.2015.08.010.
To date risk stratification in acute promyelocytic leukemia (APL) is based on highly dynamic leukocyte and platelet counts only. To identify a more robust risk stratification model, a molecular risk score was developed based on expression levels of the genes BAALC, ERG and WT1. Hereby, the main focus was on prediction of relapse. The integrative risk score divided patients into two groups with highly significant differences in outcome. It discriminated a high risk group with a high incidence of relapse successfully from a low risk group with no APL-related events after achievement of first remission. Especially the concurrent presence of molecular risk factors showed to be a negative prognostic factor in APL. The molecular risk score might be a promising approach to guide monitoring of APL patients and therapeutic decisions in the future.
迄今为止，急性早幼粒细胞白血病（APL）的风险分层仅基于高度动态变化的白细胞和血小板计数。为了确定一个更可靠的风险分层模型，基于BAALC、ERG和WT1基因的表达水平开发了一种分子风险评分。在此，主要重点是复发预测。综合风险评分将患者分为两组，其预后存在高度显著差异。它成功地将复发率高的高危组与首次缓解后无APL相关事件的低危组区分开来。特别是分子危险因素的同时存在被证明是APL的一个不良预后因素。分子风险评分可能是未来指导APL患者监测和治疗决策的一种有前景的方法。
